Hepsin shows inhibitory effects through apoptotic pathway on ovarian cancer cell lines

Keiichiro Nakamura1, Yasutomo Nasu, Atsushi Hongo

  • 1Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan. k-nakamu@cc.okayama-u.ac.jp

Insights

Hepsin gene therapy shows promise for ovarian cancer treatment by inhibiting tumor growth and promoting cell death. This research identifies Hepsin as a potential therapeutic target for improving patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gene Therapy

Background:

  • Ovarian cancer has a poor prognosis, driving the search for novel treatments beyond surgery and chemotherapy.
  • Gene therapy is a promising area, with Hepsin (a serine protease) emerging as a potential therapeutic agent.
  • The precise biological role of Hepsin expression in cancer remains largely uncharacterized.

Purpose of the Study:

  • To investigate the therapeutic potential of Hepsin in ovarian cancer.
  • To determine the effect of Hepsin expression on ovarian cancer cell growth and tumorigenicity.
  • To elucidate the molecular mechanisms underlying Hepsin's anti-cancer effects.

Main Methods:

  • Stable Hepsin transfectants were generated in ovarian cancer cell lines.
  • In vitro assays assessed cell growth inhibition (monolayer and soft agar).
  • In vivo tumorigenicity was evaluated, alongside analysis of apoptosis markers (p53, caspase-3, -6, -7).

Main Results:

  • Hepsin expression significantly inhibited ovarian cancer cell growth in vitro and reduced tumorigenicity in vivo.
  • Increased apoptotic cells were observed in Hepsin-expressing cells.
  • Hepsin up-regulated p53-dependent apoptosis and activated caspase-3, -6, and -7.

Conclusions:

  • Hepsin demonstrates significant therapeutic potential as an anti-cancer agent in ovarian cancer.
  • Hepsin inhibits ovarian cancer progression by inducing apoptosis via the p53 and caspase pathways.
  • Hepsin represents a novel molecular target for developing innovative ovarian cancer therapies.

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...